Healthcare Stocks
S&P 500 and CAC 40 2026
64 companies analyzed by the StockConviction engine. Ranked by Q-Score, from strongest to weakest fundamentals.
| # | Company | Q-Score | Conviction | Zone |
|---|---|---|---|---|
| 1 | Medpace Holdings, Inc. (MEDP) | 100/100 | No conviction | Overvalued |
| 2 | Eli Lilly and Company (LLY) | 95/100 | Patient buy conviction | Fairly valued |
| 3 | Incyte Corporation (INCY) | 89.3/100 | No conviction | Fairly valued |
| 4 | Intuitive Surgical, Inc. (ISRG) | 86.6/100 | No conviction | Overvalued |
| 5 | ResMed Inc. (RMD) | 86.4/100 | Patient buy conviction | Fairly valued |
| 6 | IDEXX Laboratories, Inc. (IDXX) | 84.2/100 | No conviction | Overvalued |
| 7 | DexCom, Inc. (DXCM) | 84/100 | No conviction | Overvalued |
| 8 | Gilead Sciences, Inc. (GILD) | 73.75/100 | – | Insufficient data |
| 9 | Insulet Corp. (PODD) | 72.5/100 | Wait for stabilization | Fairly valued |
| 10 | Vertex Pharmaceuticals Incorporated (VRTX) | 72.3/100 | No conviction | Fairly valued |
| 11 | Zoetis Inc. (ZTS) | 72.05/100 | Wait for stabilization | Undervalued |
| 12 | Merck & Co., Inc. (MRK) | 71.7/100 | No conviction | Overvalued |
| 13 | Regeneron Pharmaceuticals, Inc. (REGN) | 70.25/100 | – | Insufficient data |
| 14 | Edwards Lifesciences Corporation (EW) | 70.1/100 | No conviction | Overvalued |
| 15 | McKesson Corporation (MCK) | 66.75/100 | No conviction | Fairly valued |
| 16 | West Pharmaceutical Services, Inc. (WST) | 66.3/100 | No conviction | Overvalued |
| 17 | Waters Corporation (WAT) | 65.7/100 | No conviction | Overvalued |
| 18 | Illumina, Inc. (ILMN) | 64.5/100 | – | Insufficient quality |
| 19 | STERIS plc (STE) | 64.45/100 | – | Insufficient quality |
| 20 | Boston Scientific Corporation (BSX) | 62.8/100 | – | Insufficient quality |
| 21 | Eurofins Scientific SE (ERF.PA) | 62.15/100 | – | Insufficient quality |
| 22 | Bio-Techne Corporation (TECH) | 60.95/100 | – | Insufficient quality |
| 23 | Bristol-Myers Squibb Company (BMY) | 60.36/100 | – | Insufficient quality |
| 24 | Stryker Corporation (SYK) | 58.15/100 | – | Insufficient quality |
| 25 | Johnson & Johnson (JNJ) | 57.3/100 | – | Insufficient quality |
| 26 | Mettler-Toledo International Inc. (MTD) | 56.6/100 | – | Insufficient quality |
| 27 | Abbott Laboratories (ABT) | 56/100 | – | Insufficient quality |
| 28 | EssilorLuxottica S.A. (EL.PA) | 55.2/100 | – | Insufficient quality |
| 29 | Molina Healthcare, Inc. (MOH) | 54.3/100 | – | Insufficient quality |
| 30 | Biogen Inc. (BIIB) | 54.2/100 | – | Insufficient quality |
| 31 | Amgen Inc. (AMGN) | 52.8/100 | – | Insufficient quality |
| 32 | Sanofi (SAN.PA) | 52.65/100 | – | Insufficient quality |
| 33 | HCA Healthcare, Inc. (HCA) | 51.7/100 | – | Insufficient quality |
| 34 | Cardinal Health, Inc. (CAH) | 48.5/100 | – | Insufficient quality |
| 35 | Align Technology, Inc. (ALGN) | 47.45/100 | – | Insufficient quality |
| 36 | Universal Health Services, Inc. (UHS) | 47.25/100 | – | Insufficient quality |
| 37 | Zimmer Biomet Holdings, Inc. (ZBH) | 46.75/100 | – | Insufficient quality |
| 38 | Agilent Technologies, Inc. (A) | 44.6/100 | – | Insufficient quality |
| 39 | The Cooper Companies, Inc. (COO) | 43.6/100 | – | Insufficient quality |
| 40 | Pfizer Inc. (PFE) | 42.4/100 | – | Insufficient quality |
| 41 | Quest Diagnostics Incorporated (DGX) | 39.7/100 | – | Insufficient quality |
| 42 | Revvity, Inc. (RVTY) | 39.2/100 | – | Insufficient quality |
| 43 | AbbVie Inc. (ABBV) | 39/100 | – | Insufficient quality |
| 44 | Solventum Corporation (SOLV) | 37.5/100 | – | Insufficient quality |
| 45 | Medtronic Plc (MDT) | 36.75/100 | – | Insufficient quality |
| 46 | Danaher Corporation (DHR) | 36.25/100 | – | Insufficient quality |
| 47 | Becton, Dickinson and Company (BDX) | 35.85/100 | – | Insufficient quality |
| 48 | Cencora, Inc. (COR) | 34.8/100 | – | Insufficient quality |
| 49 | IQVIA Holdings Inc. (IQV) | 34.05/100 | – | Insufficient quality |
| 50 | Charles River Laboratories International, Inc. (CRL) | 33.6/100 | – | Insufficient quality |
| 51 | Labcorp Holdings Inc. (LH) | 33/100 | – | Insufficient quality |
| 52 | UnitedHealth Group Incorporated (UNH) | 32.6/100 | – | Insufficient quality |
| 53 | Cigna Corporation (CI) | 31.65/100 | – | Insufficient quality |
| 54 | Henry Schein, Inc. (HSIC) | 30.85/100 | – | Insufficient quality |
| 55 | Thermo Fisher Scientific Inc. (TMO) | 29.6/100 | – | Insufficient quality |
| 56 | GE HealthCare Technologies Inc. (GEHC) | 26.75/100 | – | Insufficient quality |
| 57 | Moderna, Inc. (MRNA) | 26.3/100 | – | Insufficient quality |
| 58 | Elevance Health Inc. (ELV) | 24.4/100 | – | Insufficient quality |
| 59 | Humana Inc. (HUM) | 22.6/100 | – | Insufficient quality |
| 60 | DaVita Inc. (DVA) | 13.8/100 | – | Insufficient quality |
| 61 | Centene Corp. (CNC) | 13/100 | – | Insufficient quality |
| 62 | Viatris Inc. (VTRS) | 12.2/100 | – | Insufficient quality |
| 63 | CVS Health Corp. (CVS) | 11.7/100 | – | Insufficient quality |
| 64 | Baxter International Inc. (BAX) | 1.45/100 | – | Insufficient quality |
Full analysis
Access the full analysis
The verdict is free. The Premium trial (14 days) adds the estimated value, its range and the detailed reasoning.
Start for free
Already a member? Log in